KR100774630B1 - 정신병의 치료를 위한 글라이신 섭취 억제제로서의1-(2-아미노-벤졸)-피페라진 유도체 - Google Patents
정신병의 치료를 위한 글라이신 섭취 억제제로서의1-(2-아미노-벤졸)-피페라진 유도체 Download PDFInfo
- Publication number
- KR100774630B1 KR100774630B1 KR1020067004792A KR20067004792A KR100774630B1 KR 100774630 B1 KR100774630 B1 KR 100774630B1 KR 1020067004792 A KR1020067004792 A KR 1020067004792A KR 20067004792 A KR20067004792 A KR 20067004792A KR 100774630 B1 KR100774630 B1 KR 100774630B1
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- alkyl
- piperazin
- formula
- substituted
- Prior art date
Links
- 0 CC(*)(CN(CC1)C2CCCCCCC2)CN1C(c1c(*)c(*)c(*)c(*)c1N(*)*)=O Chemical compound CC(*)(CN(CC1)C2CCCCCCC2)CN1C(c1c(*)c(*)c(*)c(*)c1N(*)*)=O 0.000 description 4
- IAOYEKYHRRKYNN-UHFFFAOYSA-N CC(CN(CC1)C(OC(C)(C)C)=O)N1c1ccc(C(F)(F)F)cc1 Chemical compound CC(CN(CC1)C(OC(C)(C)C)=O)N1c1ccc(C(F)(F)F)cc1 IAOYEKYHRRKYNN-UHFFFAOYSA-N 0.000 description 1
- AQHWJXQBTGNROA-UHFFFAOYSA-N CC(c(cc1)cc(Cl)c1N1CCNCC1)=O Chemical compound CC(c(cc1)cc(Cl)c1N1CCNCC1)=O AQHWJXQBTGNROA-UHFFFAOYSA-N 0.000 description 1
- IQSDSPFWFDLKSV-UHFFFAOYSA-N CC(c(cc1)ccc1N(CC1)CCN1C(c1cc([N+](C)=O)ccc1F)=O)=O Chemical compound CC(c(cc1)ccc1N(CC1)CCN1C(c1cc([N+](C)=O)ccc1F)=O)=O IQSDSPFWFDLKSV-UHFFFAOYSA-N 0.000 description 1
- FZYXFHOZLFSOSG-UHFFFAOYSA-N CC(c(cc1F)ccc1N(CC1)CCN1C(c1cc(C#N)ccc1Br)=O)=O Chemical compound CC(c(cc1F)ccc1N(CC1)CCN1C(c1cc(C#N)ccc1Br)=O)=O FZYXFHOZLFSOSG-UHFFFAOYSA-N 0.000 description 1
- CJHDNODBCUENAN-UHFFFAOYSA-N CCS(c(cc1)cc(C(O)=O)c1Cl)(=O)=O Chemical compound CCS(c(cc1)cc(C(O)=O)c1Cl)(=O)=O CJHDNODBCUENAN-UHFFFAOYSA-N 0.000 description 1
- YMHKSQSXGVAUEB-UHFFFAOYSA-N CS(c(cc1)cc(C(O)=O)c1N1CCCCC1)(=O)=O Chemical compound CS(c(cc1)cc(C(O)=O)c1N1CCCCC1)(=O)=O YMHKSQSXGVAUEB-UHFFFAOYSA-N 0.000 description 1
- QDVSNGFJIUPURX-UHFFFAOYSA-N CS(c(cc1C(N(CC2)CCN2c(ccc(S(C)(=O)=O)c2)c2F)=O)ccc1I)(=O)=O Chemical compound CS(c(cc1C(N(CC2)CCN2c(ccc(S(C)(=O)=O)c2)c2F)=O)ccc1I)(=O)=O QDVSNGFJIUPURX-UHFFFAOYSA-N 0.000 description 1
- FSBQPXIJIHESSS-UHFFFAOYSA-N CS(c(cc1C(O)=O)ccc1I)(=O)=O Chemical compound CS(c(cc1C(O)=O)ccc1I)(=O)=O FSBQPXIJIHESSS-UHFFFAOYSA-N 0.000 description 1
- FLQLSEFVSDVBAL-UHFFFAOYSA-N CS(c(cc1C(O)=O)ccc1N1CC(CO)CC1)(=O)=O Chemical compound CS(c(cc1C(O)=O)ccc1N1CC(CO)CC1)(=O)=O FLQLSEFVSDVBAL-UHFFFAOYSA-N 0.000 description 1
- FCNLATMNOJLXID-UHFFFAOYSA-N FC(c(nc1)ccc1N1CCNCC1)(F)F Chemical compound FC(c(nc1)ccc1N1CCNCC1)(F)F FCNLATMNOJLXID-UHFFFAOYSA-N 0.000 description 1
- OZOPJOHFUWBMJV-UHFFFAOYSA-N N#Cc(cc(c(N1CCNCC1)c1)F)c1F Chemical compound N#Cc(cc(c(N1CCNCC1)c1)F)c1F OZOPJOHFUWBMJV-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N OC(C(F)(F)F)=O Chemical compound OC(C(F)(F)F)=O DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- GOWHUHLKBKFDKK-UHFFFAOYSA-N OC(c(cc(cc1)S(N2CCOCC2)(=O)=O)c1Cl)=O Chemical compound OC(c(cc(cc1)S(N2CCOCC2)(=O)=O)c1Cl)=O GOWHUHLKBKFDKK-UHFFFAOYSA-N 0.000 description 1
- MUYVZIXUWYJVEO-UHFFFAOYSA-N OC(c(cc(cc1)S(NCC2CC2)(=O)=O)c1N1CCCC1)=O Chemical compound OC(c(cc(cc1)S(NCC2CC2)(=O)=O)c1N1CCCC1)=O MUYVZIXUWYJVEO-UHFFFAOYSA-N 0.000 description 1
- VREDAFJSOZXIOH-UHFFFAOYSA-N [O-][NH+](c(cc1)cc(C(O)=O)c1N1CCOCC1)O Chemical compound [O-][NH+](c(cc1)cc(C(O)=O)c1N1CCOCC1)O VREDAFJSOZXIOH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Description
Claims (25)
- 하기 화학식 I의 화합물 또는 그의 약학적으로 허용가능한 산 부가 염:화학식 I상기 식에서,Ar은 (i) 할로겐, NO2, CN, (C1-C6)-알킬, 할로겐으로 치환된 (C1-C6)-알킬, (C1-C6)-알콕시, 할로겐으로 치환된 (C1-C6)-알콕시, 아세틸, -COO(C1-C6)-알킬, NH2, SO2(C1-C6)-알킬 또는 SO2NH2로 치환된 페닐; (ii) 할로겐, CN, (C1-C6)-알킬 또는 할로겐으로 치환된 (C1-C6)-알킬로 치환된 피리딘; (iii) 할로겐 또는 할로겐으로 치환된 (C1-C6)-알킬로 치환된 피리미딘; (iv) 할로겐으로 치환된 (C1-C6)-알킬로 치환된 피리다진; 또는 (v) (C1-C6)-알킬아민으로 치환된 트라이아진이고;R1은 수소 또는 (C1-C6)-알킬이고;R2 및 R2'는 서로 독립적으로 수소; 하이드록시; 하이드록시, (C1-C6)-알콕시, (C3-C6)-사이클로알킬, 테트라하이드로피란 또는 테트라하이드로퓨란으로 치환되거나 비치환된 (C1-C6)-알킬; (C3-C6)-사이클로알킬; 알릴; 또는 벤질이거나; 또는R2 및 R2'가 함께 (C1-C6)-알킬로 치환되거나 비치환된 모폴린; 아제티딘; 하이드록시, (C1-C6)-알킬, (C1-C6)-알콕시로 치환된 (C1-C6)-알킬 또는 (C1-C6)-알콕시로 치환되거나 비치환된 피롤리딘; 하이드록시 또는 (C1-C6)-알킬로 치환되거나 비치환된 피페리딘; 아제판; (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬로 치환되거나 비치환된 이미다졸; 트라이아졸; 다이하이드로피롤; 싸이오모폴린; 또는 (C1-C6)-알킬로 치환되거나 비치환된 피라졸을 형성하고;R3은 수소 또는 할로겐이고;R4는 수소이고;R5는 NO2; CN; (C1-C6)-알킬로 치환되거나 비치환된 아마이드; 아세틸; S-(C1-C6)-알킬; (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬-(C1-C6)-알킬로 치환된 SO2; SO2NR7R8; 또는 NR11R12이고;R6은 수소 또는 할로겐이고;R7 및 R8은 서로 독립적으로 수소, (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬로 치환된 (C1-C6)-알킬이거나, 또는 R7 및 R8이 함께 피롤리딘 또는 모폴린을 형성하고;R11 및 R12는 서로 독립적으로 수소, SO2(C1-C6)-알킬, 테트라졸 또는 이미다졸이되,1-(4-메톡시페닐)-4-[2-(4-메틸-1-피페라진일)-5-나이트로벤조일]-피페라진,1-(4-메톡시페닐)-4-[2-(4-모폴린일)-5-나이트로벤조일]-피페라진,1-[2-(4-모폴린일)-5-나이트로벤조일]-4-[2-나이트로-4-(트라이플루오로메틸)페닐]-피페라진,1-(4-메톡시페닐)-4-[5-나이트로-2-(1-피롤리딘일)벤조일]-피페라진,1-[2-[4-(2-하이드록시에틸)-1-피페라진일]-5-나이트로벤조일]-4-(4-메톡시페닐)-피페라진,1-[2-플루오로-4-(1-옥소프로필)페닐]-4-[5-나이트로-2-(1-피페리딘일)벤조일]-피페라진,1-[2-플루오로-4-(1-옥소프로필)페닐]-4-[5-나이트로-2-(1-피롤리딘일)벤조일]-피페라진,1-[2-플루오로-4-(1-옥소프로필)페닐]-4-[2-(4-메틸-1-피페리딘일)-5-나이트로벤조일]-피페라진,1-[2-플루오로-4-(1-옥소프로필)페닐]-4-[2-(4-메틸-1-피페라진일)-5-나이트로벤조일]-피페라진,1-[2-플루오로-4-(1-옥소프로필)페닐]-4-[2-(4-모폴린일)-5-나이트로벤조일]-피페라진,1-[5-[[메틸(페닐메틸)아미노]설폰일]-2-(4-모폴린일)벤조일]-4-(4-나이트로페닐)-피페라진 및1-(4-아세틸-2-플루오로페닐)-4-[2-(4-모폴린일)-5-나이트로벤조일]-피페라진은 제외된다.
- 하기 화학식 I'의 화합물 또는 그의 약학적으로 허용가능한 산 부가 염:화학식 I'상기 식에서,Ar은 (i) 할로겐, NO2, CN, (C1-C6)-알킬, 할로겐으로 치환된 (C1-C6)-알킬, (C1-C6)-알콕시, 할로겐으로 치환된 (C1-C6)-알콕시, 아세틸, -COO(C1-C6)-알킬, NH2, SO2(C1-C6)-알킬 또는 SO2NH2로 치환된 페닐; (ii) 할로겐, CN, (C1-C6)-알킬 또는 할로겐으로 치환된 (C1-C6)-알킬로 치환된 피리딘; (iii) 할로겐 또는 할로겐으로 치환된 (C1-C6)-알킬로 치환된 피리미딘; (iv) 할로겐으로 치환된 (C1-C6)-알킬로 치환된 피리다진; 또는 (v) (C1-C6)-알킬아민으로 치환된 트라이아진이고;R1은 수소 또는 (C1-C6)-알킬이고;R2 및 R2'는 서로 독립적으로 수소; 하이드록시; 하이드록시, (C1-C6)-알콕시, (C3-C6)-사이클로알킬, 테트라하이드로피란 또는 테트라하이드로퓨란으로 치환되거나 비치환된 (C1-C6)-알킬; (C3-C6)-사이클로알킬; 알릴; 또는 벤질이거나; 또는R2 및 R2'가 함께 (C1-C6)-알킬로 치환되거나 비치환된 모폴린; 아제티딘; 하이드록시, (C1-C6)-알킬, (C1-C6)-알콕시로 치환된 (C1-C6)-알킬 또는 (C1-C6)-알콕시로 치환되거나 비치환된 피롤리딘; 하이드록시 또는 (C1-C6)-알킬로 치환되거나 비치환된 피페리딘; 아제판; (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬로 치환되거나 비치환된 이미다졸; 트라이아졸; 다이하이드로피롤; 싸이오모폴린; 또는 (C1-C6)-알킬로 치환되거나 비치환된 피라졸을 형성하고;R3은 수소 또는 할로겐이고;R4는 수소이고;R5는 NO2; CN; (C1-C6)-알킬로 치환되거나 비치환된 아마이드; 아세틸; S-(C1-C6)-알킬; (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬-(C1-C6)-알킬로 치환된 SO2; SO2NR7R8; 또는 NR11R12이고;R6은 수소 또는 할로겐이고;R7 및 R8은 서로 독립적으로 수소, (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬로 치환된 (C1-C6)-알킬이거나, 또는 R7 및 R8이 함께 피롤리딘 또는 모폴린을 형성하고;R11 및 R12는 서로 독립적으로 수소, SO2(C1-C6)-알킬, 테트라졸 또는 이미다졸이되,1-[2-[[2-(다이에틸아미노)에틸]아미노]-5-나이트로벤조일]-4-(메톡시페닐)-피페라진,1-(4-메톡시페닐)-4-[2-(4-메틸-1-피페라진일)-5-나이트로벤조일]-피페라진,1-(4-메톡시페닐)-4-[2-(4-모폴린일)-5-나이트로벤조일]-피페라진,1-[2-(4-모폴린일)-5-나이트로벤조일]-4-[2-나이트로-4-(트라이플루오로메틸)페닐]-피페라진,1-(4-메톡시페닐)-4-[5-나이트로-2-(1-피롤리딘일)벤조일]-피페라진,1-[2-[4-(2-하이드록시에틸)-1-피페라진일]-5-나이트로벤조일]-4-(4-메톡시페닐)-피페라진,1-[2-플루오로-4-(1-옥소프로필)페닐]-4-[5-나이트로-2-(1-피페리딘일)벤조일]-피페라진,1-[2-플루오로-4-(1-옥소프로필)페닐]-4-[5-나이트로-2-(1-피롤리딘일)벤조일]-피페라진,1-[2-플루오로-4-(1-옥소프로필)페닐]-4-[2-(4-메틸-1-피페리딘일)-5-나이트로벤조일]-피페라진,1-[2-플루오로-4-(1-옥소프로필)페닐]-4-[2-(4-메틸-1-피페라진일)-5-나이트로벤조일]-피페라진,1-[2-플루오로-4-(1-옥소프로필)페닐]-4-[2-(4-모폴린일)-5-나이트로벤조일]-피페라진,1-[5-[[메틸(페닐메틸)아미노]설폰일]-2-(4-모폴린일)벤조일]-4-(4-나이트로페닐)-피페라진 및1-(4-아세틸-2-플루오로페닐)-4-[2-(4-모폴린일)-5-나이트로벤조일]-피페라진은 제외된다.
- 제 1 항에 있어서,하기 화학식 I-1의 화합물 또는 그의 약학적으로 허용가능한 산 부가 염:화학식 I-1상기 식에서,R'는 할로겐, NO2, CN, (C1-C6)-알킬, 할로겐으로 치환된 (C1-C6)-알킬, (C1-C6)-알콕시, 할로겐으로 치환된 (C1-C6)-알콕시, 아세틸, -COO(C1-C6)-알킬, NH2, SO2(C1-C6)-알킬 또는 SO2NH2이고;m은 1, 2 또는 3이고;R1은 수소 또는 (C1-C6)-알킬이고;R2 및 R2'는 서로 독립적으로 수소; 하이드록시; 하이드록시, (C1-C6)-알콕시, (C3-C6)-사이클로알킬, 테트라하이드로피란 또는 테트라하이드로퓨란으로 치환되거나 비치환된 (C1-C6)-알킬; (C3-C6)-사이클로알킬; 알릴; 또는 벤질이고;R3은 수소 또는 할로겐이고;R4는 수소이고;R5는 NO2; CN; (C1-C6)-알킬로 치환되거나 비치환된 아마이드; 아세틸; S-(C1-C6)-알킬; (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬-(C1-C6)-알킬로 치환된 SO2; SO2NR7R8; 또는 NR11R12이고;R6은 수소 또는 할로겐이고;R7 및 R8은 서로 독립적으로 수소, (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬로 치환된 (C1-C6)-알킬이거나, 또는 R7 및 R8이 함께 피롤리딘 또는 모폴린을 형성하고;R11 및 R12는 서로 독립적으로 수소, SO2(C1-C6)-알킬, 테트라졸 또는 이미다졸이다.
- 제 3 항에 있어서,1-(4-{4-[2-(사이클로프로필메틸-아미노)-5-나이트로-벤조일]-피페라진-1-일}-3-플루오로-페닐)-에탄온,1-{4-[4-(2-사이클로헥실아미노-5-나이트로-벤조일)-피페라진-1-일]-3-플루오로-페닐}-에탄온,1-{4-[4-(2-다이에틸아미노-5-나이트로-벤조일)-피페라진-1-일]-3-플루오로-페닐}-에탄온,1-{3-플루오로-4-[4-(2-아이소부틸아미노-5-나이트로-벤조일)-피페라진-1-일]-페닐}-에탄온,1-{4-[4-(2-사이클로부틸아미노-5-나이트로-벤조일)-피페라진-1-일]-3-플루오로-페닐}-에탄온,1-{4-[4-(2-사이클로부틸아미노-5-나이트로-벤조일)-피페라진-1-일]-3-플루오로-페닐}-에탄온,1-{4-[4-(2-사이클로펜틸아미노-5-나이트로-벤조일)-피페라진-1-일]-3-플루오로-페닐}-에탄온 또는1-(4-{4-[2-(알릴-메틸-아미노)-5-나이트로-벤조일]-피페라진-1-일}-3-플루오로-페닐)-에탄온인 화학식 I-1의 화합물.
- 제 1 항에 있어서,하기 화학식 I-2의 화합물 또는 그의 약학적으로 허용가능한 산 부가 염:화학식 I-2상기 식에서,R'는 할로겐, NO2, CN, (C1-C6)-알킬, 할로겐으로 치환된 (C1-C6)-알킬, (C1-C6)-알콕시, 할로겐으로 치환된 (C1-C6)-알콕시, 아세틸, -COO(C1-C6)-알킬, NH2, SO2(C1-C6)-알킬 또는 SO2NH2이고;m은 1, 2 또는 3이고;R1은 수소 또는 (C1-C6)-알킬이고;은 (C1-C6)-알킬로 치환되거나 비치환된 모폴린; 아제티딘; 하이드록시, (C1-C6)-알킬, (C1-C6)-알콕시로 치환된 (C1-C6)-알킬 또는 (C1-C6)-알콕시로 치환되거나 비치환된 피롤리딘; 하이드록시 또는 (C1-C6)-알킬로 치환되거나 비치환된 피페리딘; 아제판; (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬로 치환되거나 비치환된 이미다졸; 트라이아졸; 다이하이드로피롤; 싸이오모폴린; 또는 (C1-C6)-알킬로 치환되거나 비치환된 피라졸이고;R3은 수소 또는 할로겐이고;R4는 수소이고;R5는 NO2; CN; (C1-C6)-알킬로 치환되거나 비치환된 아마이드; 아세틸; S-(C1-C6)-알킬; (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬-(C1-C6)-알킬로 치환된 SO2; SO2NR7R8; 또는 NR11R12이고;R6은 수소 또는 할로겐이고;R7 및 R8은 서로 독립적으로 수소, (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬로 치환된 (C1-C6)-알킬이거나, 또는 R7 및 R8이 함께 피롤리딘 또는 모폴린을 형성하고;R11 및 R12는 서로 독립적으로 수소, SO2(C1-C6)-알킬, 테트라졸 또는 이미다졸이다.
- 제 5 항에 있어서,1-{4-[4-(2-모폴린-4-일-5-나이트로-벤조일)-피페라진-1-일]-3-플루오로-페닐}-에탄온,1-{3-플루오로-4-[4-(5-나이트로-2-피롤리딘-1-일-벤조일)-피페라진-1-일]-페닐}-에탄온,1-{3-플루오로-4-[4-(5-나이트로-2-피페리딘-1-일-벤조일)-피페라진-1-일]-페닐}-에탄온,1-{4-[4-(2-아제판-1-일-5-나이트로-벤조일)-피페라진-1-일]-3-플루오로-페닐}-에탄온,1-(3-플루오로-4-{4-[2-(2-메틸-피페리딘-1-일)-5-나이트로-벤조일]-피페라진-1-일}-페닐)-에탄온,1-(3-플루오로-4-{4-[2-(4-메틸-피페리딘-1-일)-5-나이트로-벤조일]-피페라진-1-일}-페닐)-에탄온,1-(3-플루오로-4-{4-[2-(3-메틸-피페리딘-1-일)-5-나이트로-벤조일]-피페라진-1-일}-페닐)-에탄온,1-(3-플루오로-4-{4-[2-(2-메틸-피롤리딘-1-일)-5-나이트로-벤조일]-피페라진-1-일}-페닐)-에탄온,1-(4-{4-[2-(2,5-다이하이드로-피롤-1-일)-5-나이트로-벤조일]-피페라진-1-일}-3-플루오로-페닐)-에탄온,1-{3-플루오로-4-[4-(5-나이트로-2-싸이오모폴린-4-일-벤조일)-피페라진-1-일]-페닐}-에탄온,1-(3-플루오로-4-{4-[2-(3-하이드록시-피페리딘-1-일)-5-나이트로-벤조일]-피페라진-1-일}-페닐)-에탄온,1-{4-[4-(2-아제판-1-일-5-메탄설폰일-벤조일)-피페라진-1-일]-3-플루오로-페닐}-에탄온,1-{3-플루오로-4-[4-(5-메탄설폰일-2-피롤리딘-1-일-벤조일)-피페라진-1-일]-페닐}-에탄온,N-메틸-4-피롤리딘-1-일-3-[4-(4-트라이플루오로메틸-페닐)-피페라진-1-카보닐]-벤젠설폰아마이드,N-메틸-4-모폴린-4-일-3-[4-(4-트라이플루오로메틸-페닐)-피페라진-1-카보닐]-벤젠설폰아마이드,3-[4-(4-아세틸-2-플루오로-페닐)-피페라진-1-카보닐]-N-메틸-4-피롤리딘-1-일-벤젠설폰아마이드,1-(3-플루오로-4-{4-[2-(3-하이드록시메틸-피롤리딘-1-일)-5-나이트로-벤조일]-피페라진-1-일}-페닐)-에탄온,2-[4-(2-모폴린-4-일-5-나이트로-벤조일)-피페라진-1-일]-5-트라이플루오로메틸-벤조나이트릴,3-플루오로-4-[4-(5-메탄설폰일-2-피페리딘-1-일-벤조일)-피페라진-1-일]-벤조나이트릴,2-플루오로-4-[4-(5-메탄설폰일-2-피페리딘-1-일-벤조일)-피페라진-1-일]-벤조나이트릴,[4-(2-플루오로-4-트라이플루오로메틸-페닐)-피페라진-1-일]-(5-메탄설폰일-2-피페리딘-1-일-페닐)-메탄온,[4-(3-플루오로-4-트라이플루오로메틸-페닐)-피페라진-1-일]-(5-메탄설폰일-2-피페리딘-1-일-페닐)-메탄온,3-[4-(4-시아노-페닐)-피페라진-1-카보닐]-N-메틸-4-피롤리딘-1-일-벤젠설폰아마이드,3-[4-(4-시아노-2-플루오로-페닐)-피페라진-1-카보닐]-N-메틸-4-피롤리딘-1-일-벤젠설폰아마이드,3-[4-(2-플루오로-4-트라이플루오로메틸-페닐)-피페라진-1-카보닐]-N-메틸-4-피롤리딘-1-일-벤젠설폰아마이드,3-[4-(3-플루오로-4-트라이플루오로메틸-페닐)-피페라진-1-카보닐]-N-메틸-4-피롤리딘-1-일-벤젠설폰아마이드,3-[4-(4-아세틸-2-플루오로-페닐)-피페라진-1-카보닐]-N-메틸-4-피페리딘-1-일-벤젠설폰아마이드,3-[4-(4-시아노-페닐)-피페라진-1-카보닐]-N-메틸-4-피페리딘-1-일-벤젠설폰아마이드,3-[4-(4-시아노-2-플루오로-페닐)-피페라진-1-카보닐]-N-메틸-4-피페리딘-1-일-벤젠설폰아마이드,3-[4-(4-시아노-3-플루오로-페닐)-피페라진-1-카보닐]-N-메틸-4-피페리딘-1-일-벤젠설폰아마이드,N-메틸-4-피페리딘-1-일-3-[4-(4-트라이플루오로메틸-페닐)-피페라진-1-카보닐]-벤젠설폰아마이드,3-[4-(2-플루오로-4-트라이플루오로메틸-페닐)-피페라진-1-카보닐]-N-메틸-4-피페리딘-1-일-벤젠설폰아마이드,3-[4-(2-플루오로-4-트라이플루오로메틸-페닐)-피페라진-1-카보닐]-N-메틸-4-피페리딘-1-일-벤젠설폰아마이드,3-[4-(2-플루오로-4-트라이플루오로메틸-페닐)-피페라진-1-카보닐]-N-메틸-4-모폴린-4-일-벤젠설폰아마이드 또는3-[4-(3-플루오로-4-트라이플루오로메틸-페닐)-피페라진-1-카보닐]-N-메틸-4-모폴린-4-일-벤젠설폰아마이드인 화학식 I-2의 화합물.
- 제 1 항에 있어서,하기 화학식 I-3의 화합물 또는 그의 약학적으로 허용가능한 산 부가 염:화학식 I-3상기 식에서,헤트아릴(hetaryl)은 (i) 할로겐, CN, (C1-C6)-알킬 또는 할로겐으로 치환된 (C1-C6)-알킬로 치환된 피리딘; (ii) 할로겐 또는 할로겐으로 치환된 (C1-C6)-알킬로 치환된 피리미딘; (iii) 할로겐으로 치환된 (C1-C6)-알킬로 치환된 피리다진; 또는 (iv) (C1-C6)-알킬아민으로 치환된 트라이아진이고;R1은 수소 또는 (C1-C6)-알킬이고;R2 및 R2'는 서로 독립적으로 수소; 하이드록시; 하이드록시, (C1-C6)-알콕시, (C3-C6)-사이클로알킬, 테트라하이드로피란 또는 테트라하이드로퓨란으로 치환되거나 비치환된 (C1-C6)-알킬; (C3-C6)-사이클로알킬; 알릴; 또는 벤질이고;R3은 수소 또는 할로겐이고;R4는 수소이고;R5는 NO2; CN; (C1-C6)-알킬로 치환되거나 비치환된 아마이드; 아세틸; S-(C1-C6)-알킬; (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬-(C1-C6)-알킬로 치환된 SO2; SO2NR7R8; 또는 NR11R12이고;R6은 수소 또는 할로겐이고;R7 및 R8은 서로 독립적으로 수소, (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬로 치환된 (C1-C6)-알킬이거나, 또는 R7 및 R8이 함께 피롤리딘 또는 모폴린을 형성하고;R11 및 R12는 서로 독립적으로 수소, SO2(C1-C6)-알킬, 테트라졸 또는 이미다졸이다.
- 제 1 항에 있어서,하기 화학식 I-4의 화합물 또는 그의 약학적으로 허용가능한 산 부가 염:화학식 I-4상기 식에서,헤트아릴은 (i) 할로겐, CN, (C1-C6)-알킬 또는 할로겐으로 치환된 (C1-C6)-알킬로 치환된 피리딘; (ii) 할로겐 또는 할로겐으로 치환된 (C1-C6)-알킬로 치환된 피리미딘; (iii) 할로겐으로 치환된 (C1-C6)-알킬로 치환된 피리다진; 또는 (iv) (C1-C6)-알킬아민으로 치환된 트라이아진이고;R1은 수소 또는 (C1-C6)-알킬이고;은 (C1-C6)-알킬로 치환되거나 비치환된 모폴린; 아제티딘; 하이드록시, (C1-C6)-알킬, (C1-C6)-알콕시로 치환된 (C1-C6)-알킬 또는 (C1-C6)-알콕시로 치환되거나 비치환된 피롤리딘; 하이드록시 또는 (C1-C6)-알킬로 치환되거나 비치환된 피페리딘; 아제판; (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬로 치환되거나 비치환된 이미다졸; 트라이아졸; 다이하이드로피롤; 싸이오모폴린; 또는 (C1-C6)-알킬로 치환되거나 비치환된 피라졸이고;R3은 수소 또는 할로겐이고;R4는 수소이고;R5는 NO2; CN; (C1-C6)-알킬로 치환되거나 비치환된 아마이드; 아세틸; S-(C1-C6)-알킬; (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬-(C1-C6)-알킬로 치환된 SO2; SO2NR7R8; 또는 NR11R12이고;R6은 수소 또는 할로겐이고;R7 및 R8은 서로 독립적으로 수소, (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬로 치환된 (C1-C6)-알킬이거나, 또는 R7 및 R8이 함께 피롤리딘 또는 모폴린을 형성하고;R11 및 R12는 서로 독립적으로 수소, SO2(C1-C6)-알킬, 테트라졸 또는 이미다졸이다.
- 제 8 항에 있어서,3-[4-(3-플루오로-4-트라이플루오로메틸-페닐)-피페라진-1-카보닐]-N-메틸-4-모폴린-4-일-벤젠설폰아마이드,(2-모폴린-4-일-5-나이트로-페닐)-[4-(5-트라이플루오로메틸-피리딘-2-일)-피페라진-1-일]-메탄온,[4-(3-클로로-5-트라이플루오로메틸-피리딘-2-일)-피페라진-1-일]-(2-모폴린-4-일-5-나이트로-페닐)-메탄온,6-[4-(2-모폴린-4-일-5-나이트로-벤조일)-피페라진-1-일]-니코티노나이트릴,[4-(3-클로로-피리딘-2-일)-피페라진-1-일]-(2-모폴린-4-일-5-나이트로-페닐)-메탄온,(2-모폴린-4-일-5-나이트로-페닐)-[4-(4-트라이플루오로메틸-피리딘-2-일)-피페라진-1-일]-메탄온,(2-모폴린-4-일-5-나이트로-페닐)-[4-(6-트라이플루오로메틸-피리딘-2-일)-피페라진-1-일]-메탄온,[4-(5-브로모-피리미딘-2-일)-피페라진-1-일]-(2-모폴린-4-일-5-나이트로-페닐)-메탄온,[4-(6-클로로-5-트라이플루오로메틸-피리딘-2-일)-피페라진-1-일]-(2-모폴린-4-일-5-나이트로-페닐)-메탄온,(5-메탄설폰일-2-모폴린-4-일-페닐)-[4-(2-트라이플루오로메틸-피리미딘-4-일)-피페라진-1-일]-메탄온,(5-메탄설폰일-2-모폴린-4-일-페닐)-[4-(6-트라이플루오로메틸-피리미딘-4-일)-피페라진-1-일]-메탄온,(5-메탄설폰일-2-모폴린-4-일-페닐)-[4-(5-트라이플루오로메틸-피리미딘-2-일)-피페라진-1-일]-메탄온,6-[4-(5-메탄설폰일-2-모폴린-4-일-벤조일)-피페라진-1-일]-니코티노나이트릴,(5-메탄설폰일-2-모폴린-4-일-페닐)-[4-(5-트라이플루오로메틸-피리딘-2-일)-피페라진-1-일]-메탄온,[4-(3-클로로-5-트라이플루오로메틸-피리딘-2-일)-피페라진-1-일]-(5-메탄설폰일-2-모폴린-4-일-페닐)-메탄온,[4-(5-클로로-피리딘-2-일)-피페라진-1-일]-(5-메탄설폰일-2-모폴린-4-일-페닐)-메탄온,(5-메탄설폰일-2-모폴린-4-일-페닐)-[4-(6-트라이플루오로메틸-피리딘-3-일)-피페라진-1-일]-메탄온,[4-(3-플루오로-5-트라이플루오로메틸-피리딘-2-일)-피페라진-1-일]-(5-메탄설폰일-2-모폴린-4-일-페닐)-메탄온,(5-메탄설폰일-2-모폴린-4-일-페닐)-[4-(6-메틸-피리딘-3-일)-피페라진-1-일]-메탄온,(5-메탄설폰일-2-모폴린-4-일-페닐)-[4-(5-메틸-피리딘-2-일)-피페라진-1-일]-메탄온,(5-메탄설폰일-2-모폴린-4-일-페닐)-[4-(4-트라이플루오로메틸-피리딘-2-일)-피페라진-1-일]-메탄온,(5-메탄설폰일-2-모폴린-4-일-페닐)-[4-(6-트라이플루오로메틸-피리딘-2-일)-피페라진-1-일]-메탄온,(5-메탄설폰일-2-모폴린-4-일-페닐)-[4-(2-트라이플루오로메틸-피리미딘-5-일)-피페라진-1-일]-메탄온,(5-메탄설폰일-2-모폴린-4-일-페닐)-[4-(6-트라이플루오로메틸-피리다진-3-일)-피페라진-1-일]-메탄온,[4-(4-다이메틸아미노-[1,3,5]트라이아진-2-일)-피페라진-1-일]-(5-메탄설폰일-2-모폴린-4-일-페닐)-메탄온 또는(5-메탄설폰일-2-모폴린-4-일-페닐)-(5'-트라이플루오로메틸-2,3,5,6-테트라하이드로[1,2']바이피라진일-4-일)-메탄온인 화학식 I-4의 화합물.
- 제 1 항에 있어서,제 10 항의 방법 또는 그와 동등한 방법에 의해 제조된 화합물.
- 하나 이상의 제 1 항에 따른 화합물 또는 하기 화합물, 및 약학적으로 허용가능한 부형제를 함유하는,정신병, 통증, 기억 및 학습기능장애, 정신분열증, 치매, 주의력결핍증 및 알츠하이머병으로 구성된 군에서 선택된 질병을 치료하기 위한 약제:1-(4-메톡시페닐)-4-[2-(4-메틸-1-피페라진일)-5-나이트로벤조일]-피페라진,1-(4-메톡시페닐)-4-[2-(4-모폴린일)-5-나이트로벤조일]-피페라진,1-[2-(4-모폴린일)-5-나이트로벤조일]-4-[2-나이트로-4-(트라이플루오로메틸)페닐]-피페라진,1-(4-메톡시페닐)-4-[5-나이트로-2-(1-피롤리딘일)벤조일]-피페라진,1-[2-[4-(2-하이드록시에틸)-1-피페라진일]-5-나이트로벤조일]-4-(4-메톡시페닐)-피페라진,1-[2-플루오로-4-(1-옥소프로필)페닐]-4-[5-나이트로-2-(1-피페리딘일)벤조일]-피페라진,1-[2-플루오로-4-(1-옥소프로필)페닐]-4-[5-나이트로-2-(1-피롤리딘일)벤조일]-피페라진,1-[2-플루오로-4-(1-옥소프로필)페닐]-4-[2-(4-메틸-1-피페리딘일)-5-나이트로벤조일]-피페라진,1-[2-플루오로-4-(1-옥소프로필)페닐]-4-[2-(4-메틸-1-피페라진일)-5-나이트로벤조일]-피페라진,1-[2-플루오로-4-(1-옥소프로필)페닐]-4-[2-(4-모폴린일)-5-나이트로벤조일]-피페라진,1-[5-[[메틸(페닐메틸)아미노]설폰일]-2-(4-모폴린일)벤조일]-4-(4-나이트로페닐)-피페라진,1-(4-아세틸-2-플루오로페닐)-4-[2-(4-모폴린일)-5-나이트로벤조일]-피페라진,1-{4-[4-(2-모폴린-4-일-5-나이트로-벤조일)-피페라진-1-일]-3-플루오로-페닐}-에탄온 또는[4-(4-메톡시-페닐)-피페라진-1-일]-(2-모폴린-4-일-5-나이트로-페닐)-메탄온.
- 삭제
- 삭제
- 삭제
- 삭제
- (j) 하기 화학식 X의 화합물을 하기 화학식 XII의 화합물과 반응시켜 하기 화학식 Ii의 화합물을 수득하는 단계, 및 경우에 따라 상기 수득된 화합물을 약학적으로 허용가능한 산 부가 염으로 전환시키는 단계를 포함하는, 하기 화학식 I의 화합물 또는 그의 약학적으로 허용가능한 염의 제조방법:화학식 X화학식 XII화학식 Ii화학식 I상기 식에서,X는 CH 또는 N이고, 헤테로아릴 고리는 이미다졸, 피라졸 및 트라이아졸로 구성된 군에서 선택되고;R15는 수소, 할로겐, (C1-C6)-알킬, 할로겐으로 치환된 (C1-C6)-알킬 또는 (C3-C6)-사이클로알킬이고;다른 치환체는 제 1 항에서 정의된 바와 같다.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03019686 | 2003-09-09 | ||
EP03019686.9 | 2003-09-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060037464A KR20060037464A (ko) | 2006-05-03 |
KR100774630B1 true KR100774630B1 (ko) | 2007-11-08 |
Family
ID=34259149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067004792A KR100774630B1 (ko) | 2003-09-09 | 2004-08-30 | 정신병의 치료를 위한 글라이신 섭취 억제제로서의1-(2-아미노-벤졸)-피페라진 유도체 |
Country Status (23)
Country | Link |
---|---|
US (2) | US7427612B2 (ko) |
EP (1) | EP1663232B1 (ko) |
JP (1) | JP4563386B2 (ko) |
KR (1) | KR100774630B1 (ko) |
CN (1) | CN1874777B (ko) |
AR (1) | AR045602A1 (ko) |
AT (1) | ATE374610T1 (ko) |
AU (1) | AU2004269889B2 (ko) |
BR (1) | BRPI0414209B8 (ko) |
CA (1) | CA2537292C (ko) |
DE (1) | DE602004009323T2 (ko) |
DK (1) | DK1663232T3 (ko) |
ES (1) | ES2294529T3 (ko) |
IL (1) | IL173768A0 (ko) |
MX (1) | MXPA06002727A (ko) |
NO (1) | NO20060768L (ko) |
NZ (1) | NZ545454A (ko) |
PL (1) | PL1663232T3 (ko) |
PT (1) | PT1663232E (ko) |
RU (1) | RU2354653C2 (ko) |
TW (1) | TWI295287B (ko) |
WO (1) | WO2005023260A1 (ko) |
ZA (1) | ZA200601990B (ko) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004020674D1 (de) * | 2003-09-09 | 2009-05-28 | Hoffmann La Roche | 1-benzoyl-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen |
CA2537292C (en) * | 2003-09-09 | 2013-04-02 | F. Hoffmann-La Roche Ag | 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses |
GB0408772D0 (en) * | 2004-04-20 | 2004-05-26 | Glaxo Group Ltd | Compounds |
MX2007003318A (es) | 2004-09-20 | 2007-05-18 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
AU2005286647A1 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
CN101084207A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途 |
MX2007003327A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa. |
EP2269610A3 (en) | 2004-09-20 | 2011-03-09 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
CA2580845A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
BRPI0515488A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados de heterocìclicos e seu uso como agentes terapêuticos |
AU2005313581B2 (en) | 2004-12-09 | 2011-06-09 | F. Hoffmann-La Roche Ag | Phenyl-piperazin methanone derivatives |
RU2007121768A (ru) * | 2004-12-15 | 2009-01-27 | Ф. Хоффманн-Ля Рош Аг (Ch) | Би- и трициклически замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 (glyt-1) для лечения болезни альцгеймера |
EP1874721A2 (en) * | 2004-12-23 | 2008-01-09 | Glaxo Group Limited | Glycine transport inhibitors |
PE20061156A1 (es) | 2004-12-23 | 2006-12-16 | Glaxo Group Ltd | Derivados de benzamida como agentes inhibidores del transportador de glicina |
GB0428233D0 (en) * | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Compounds |
US7485637B2 (en) * | 2005-01-04 | 2009-02-03 | Hoffmann-La Roche Inc. | Benzoyl-tetrahydropiperidine derivatives |
JP2008526795A (ja) * | 2005-01-06 | 2008-07-24 | エフ.ホフマン−ラ ロシュ アーゲー | 神経障害および神経精神疾患を処置するためのグリシントランスポータ1(glyt−1)阻害物質としての、スルファニル置換フェニルメタノン |
EP1838308B1 (en) | 2005-01-07 | 2010-06-30 | F. Hoffmann-Roche AG | [4-(heteroaryl)piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
KR100935256B1 (ko) * | 2005-01-18 | 2010-01-06 | 에프. 호프만-라 로슈 아게 | 신경 질환 및 신경정신 질환의 치료를 위한 글라이신트랜스포터 1(glyt-1) 억제제로서의 2,5-이치환된 페닐메탄온 유도체 |
RU2007126951A (ru) * | 2005-01-26 | 2009-03-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные фенилметанона и их применение в качестве ингибиторов переносчика глицина 1 |
JP4647670B2 (ja) * | 2005-02-07 | 2011-03-09 | エフ.ホフマン−ラ ロシュ アーゲー | グリシントランスポーター1の阻害剤としてのヘテロシクリル置換フェニルメタノン |
GB0505084D0 (en) * | 2005-03-11 | 2005-04-20 | Glaxo Group Ltd | Compounds |
GB0505086D0 (en) * | 2005-03-11 | 2005-04-20 | Glaxo Group Ltd | Compounds |
GB0505085D0 (en) * | 2005-03-11 | 2005-04-20 | Glaxo Group Ltd | Compounds |
JP2009513563A (ja) | 2005-06-03 | 2009-04-02 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトのステアロイル−CoAデサチュラーゼ阻害剤としてのアミノチアゾール誘導体 |
CN101007794B (zh) * | 2006-01-26 | 2010-09-01 | 中国科学院上海药物研究所 | N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途 |
MX2009014235A (es) | 2007-08-22 | 2010-04-27 | Abbott Gmbh & Co Kg | 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso. |
JP5441705B2 (ja) | 2007-10-15 | 2014-03-12 | 武田薬品工業株式会社 | アミド化合物およびその用途 |
US8263630B2 (en) | 2008-02-12 | 2012-09-11 | Bristol-Myers Squibb Company | 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type I inhibitors |
JP5554319B2 (ja) | 2008-04-01 | 2014-07-23 | アボット ゲーエムベーハー ウント カンパニー カーゲー | テトラヒドロイソキノリン類、それを含む医薬組成物および治療におけるそれの使用 |
CN101597278B (zh) | 2008-06-04 | 2013-04-17 | 中国中化股份有限公司 | 酰胺类化合物及其制备与应用 |
AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
CN105693601A (zh) | 2009-08-24 | 2016-06-22 | 纽若斯丹公司 | 神经刺激性哌嗪的合成 |
MX2012012555A (es) * | 2010-04-27 | 2013-03-18 | Mitsubishi Tanabe Pharma Corp | Derivado novedoso de amida y su uso como medicina. |
US8153653B2 (en) * | 2010-06-22 | 2012-04-10 | Hoffmann-La Roche Inc. | Amido-tropane derivatives |
US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
EP2739614B1 (en) | 2011-08-05 | 2017-02-22 | AbbVie Deutschland GmbH & Co KG | AMINOCHROMANEs, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY |
JP5800786B2 (ja) * | 2011-10-26 | 2015-10-28 | 田辺三菱製薬株式会社 | 新規アミド誘導体を有効成分として含有する医薬組成物 |
WO2013072520A1 (en) | 2011-11-18 | 2013-05-23 | AbbVie Deutschland GmbH & Co. KG | N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
AU2014336153A1 (en) | 2013-10-17 | 2016-04-28 | AbbVie Deutschland GmbH & Co. KG | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
WO2015055771A1 (en) | 2013-10-17 | 2015-04-23 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
MA39888A (fr) | 2014-04-24 | 2017-03-01 | Dart Neuroscience Cayman Ltd | Composés de 2,4,5,6-tétrahydropyrrolo[3,4-c] pyrazole et 4,5,6,7-tétrahydro-2 h-pyrazolo [4,3-c] pyridine utilisés comme inhibiteurs de glyt1 |
US9550754B2 (en) | 2014-09-11 | 2017-01-24 | AbbVie Deutschland GmbH & Co. KG | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy |
WO2016073420A1 (en) | 2014-11-05 | 2016-05-12 | Dart Neuroscience, Llc | Substituted azetidinyl compounds as glyt1 inhibitors |
AU2019280689A1 (en) | 2018-06-05 | 2021-01-21 | Crinetics Pharmaceuticals, Inc. | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof |
CN114409621B (zh) * | 2022-02-09 | 2023-09-08 | 江苏省原子医学研究所 | 一种靶向多巴胺d3受体的诊疗药物及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0171636A1 (en) * | 1984-08-14 | 1986-02-19 | RAVIZZA S.p.A. | Pharmacologically active piperazino derivatives and the process for their preparation |
WO1999044596A2 (en) * | 1998-03-06 | 1999-09-10 | Janssen Pharmaceutica N.V. | Glycine transport inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2423847A1 (de) * | 1973-05-28 | 1975-01-02 | Ciba Geigy Ag | Neue sulfamoylbenzoesaeureamide |
DE2611705A1 (de) * | 1976-03-18 | 1977-09-22 | Josef Dipl Chem Dr Rer N Klosa | N-5-(nitrofurfuryliden-)-1-amino- hydantoin enthaltende kristalloesungsmittel |
ES2297458T3 (es) * | 2003-08-11 | 2008-05-01 | F. Hoffmann-La Roche Ag | Piperazina con grupo fenilo or-sustituido y su empleo como inhibidores de glyti. |
DE602004020674D1 (de) * | 2003-09-09 | 2009-05-28 | Hoffmann La Roche | 1-benzoyl-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen |
CA2537292C (en) * | 2003-09-09 | 2013-04-02 | F. Hoffmann-La Roche Ag | 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses |
US7191925B2 (en) * | 2003-09-16 | 2007-03-20 | Aris Sandra M | Clean carry apparatus |
-
2004
- 2004-08-30 CA CA2537292A patent/CA2537292C/en not_active Expired - Fee Related
- 2004-08-30 PL PL04764631T patent/PL1663232T3/pl unknown
- 2004-08-30 BR BRPI0414209A patent/BRPI0414209B8/pt not_active IP Right Cessation
- 2004-08-30 CN CN2004800321632A patent/CN1874777B/zh active Active
- 2004-08-30 PT PT04764631T patent/PT1663232E/pt unknown
- 2004-08-30 RU RU2006111583/04A patent/RU2354653C2/ru not_active IP Right Cessation
- 2004-08-30 WO PCT/EP2004/009665 patent/WO2005023260A1/en active IP Right Grant
- 2004-08-30 KR KR1020067004792A patent/KR100774630B1/ko active IP Right Grant
- 2004-08-30 AT AT04764631T patent/ATE374610T1/de active
- 2004-08-30 ES ES04764631T patent/ES2294529T3/es active Active
- 2004-08-30 EP EP04764631A patent/EP1663232B1/en active Active
- 2004-08-30 AU AU2004269889A patent/AU2004269889B2/en not_active Ceased
- 2004-08-30 NZ NZ545454A patent/NZ545454A/en unknown
- 2004-08-30 MX MXPA06002727A patent/MXPA06002727A/es active IP Right Grant
- 2004-08-30 DE DE602004009323T patent/DE602004009323T2/de active Active
- 2004-08-30 JP JP2006525694A patent/JP4563386B2/ja active Active
- 2004-08-30 DK DK04764631T patent/DK1663232T3/da active
- 2004-09-02 US US10/933,103 patent/US7427612B2/en active Active
- 2004-09-03 TW TW093126741A patent/TWI295287B/zh not_active IP Right Cessation
- 2004-09-07 AR ARP040103200A patent/AR045602A1/es not_active Application Discontinuation
-
2006
- 2006-02-16 IL IL173768A patent/IL173768A0/en active IP Right Grant
- 2006-02-17 NO NO20060768A patent/NO20060768L/no not_active Application Discontinuation
- 2006-03-08 ZA ZA200601990A patent/ZA200601990B/en unknown
-
2008
- 2008-07-22 US US12/177,386 patent/US7595314B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0171636A1 (en) * | 1984-08-14 | 1986-02-19 | RAVIZZA S.p.A. | Pharmacologically active piperazino derivatives and the process for their preparation |
WO1999044596A2 (en) * | 1998-03-06 | 1999-09-10 | Janssen Pharmaceutica N.V. | Glycine transport inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100774630B1 (ko) | 정신병의 치료를 위한 글라이신 섭취 억제제로서의1-(2-아미노-벤졸)-피페라진 유도체 | |
JP4252598B2 (ja) | Or置換フェニル基を有するピペラジン及びglyt1阻害剤としてのこれらの使用 | |
KR100774621B1 (ko) | 정신병 치료용의 글라이신 섭취 억제제로서의1-벤조일-피페라진 유도체 | |
CN106573915B (zh) | 针对布罗莫结构域有活性的化合物 | |
CN103429585B (zh) | 作为白细胞介素-1受体相关激酶抑制剂的吲唑基三唑衍生物 | |
CN111094278A (zh) | 二苯基衍生物及其用途 | |
KR20070094955A (ko) | 신경 질환 및 신경정신 질환을 치료하기 위한 글라이신수송자 1(glyt-1) 저해제로서의 설파닐 치환 페닐메타논 | |
KR101072796B1 (ko) | 치환된 페닐 메탄온 유도체 | |
JP2023527055A (ja) | がんの治療に使用するためのlimk及び/又はrockキナーゼ阻害剤としての4-(7h-ピロロ[2,3-d]ピリミジン-4-イル)-3,6-ジヒドロピリジン-1-(2h)-カルボキサミド誘導体 | |
KR100935256B1 (ko) | 신경 질환 및 신경정신 질환의 치료를 위한 글라이신트랜스포터 1(glyt-1) 억제제로서의 2,5-이치환된 페닐메탄온 유도체 | |
CN117396475A (zh) | 抗菌化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121030 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20131030 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20141030 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150930 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20161028 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170929 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180928 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190924 Year of fee payment: 13 |